Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers

Comprising less than 1% of all the adult malignancies, and inflicting pain in more than one body organ, the rarity and heterogeneity of sarcomas make it difficult to diagnose, treat and run a clinical trial resulting in efficient outcomes. The reason, why Soft tissue sarcoma market (STS market) has limited treatment options leaving the small part of the population living with STS helpless. 

At present, there exist more than 50 histological forms of Soft tissue sarcoma, as per WHO. 

According to a survey done by AACR Project GENIE, the most understood underlying cause of Soft tissue sarcoma is altered genes; and the genes mostly harboring mutation, hence responsible for the sarcoma – in soft tissues such as adipose, connective, muscles; and blood vessels, are TP53, RB1, CDKN2A, ATRX, and CDKN2B, along with others including NF1, TERT, and others. 

As per DelveInsight’s Soft tissue sarcoma Epidemiological analysis, the total incident population in the 7MM was observed to be around 40,155 cases. The US accounted for the highest STS incidence, with 12,390 cases, in the year 2017 in the 7MM, with Spain observed to be accounting for the least Soft tissue cases. Moreover, analysts forecast that STS incidence is going to rise in the coming decade, which offers a potential opportunity to the pharma and biotech players and healthcare institutions to advance their research in STS to find a standard approach to enter Soft tissue sarcoma market. 

DelveInsight’s market analysis estimated that in 2017, Soft tissue sarcoma market size is going to increase with a CAGR of 6.47% During the Study Period for 7MM. As per analysts, the STS market size is going to increase during the study period 2017-30, attributed to rising in STS incidence, upcoming Soft tissue sarcoma therapies in the pipeline. In addition to this, the recent approval of Vitrakvi, and Rozlytrek is also lending a hand in increasing Soft tissue market size. 

Present STS market landscape and clinical research are evaluating multiple molecular pathways, and mechanisms testing the function of antagonist antibodies, TK inhibitors, and inhibitors of downstream molecules of PI3K, MAPK, and mTOR paths. However, among all of these, TK inhibitors have caught the attention of many researchers and pharma companies after the approval of imatinib for GIST in 2012. 

Many Pharmaceutical and biotech players like Blueprint Medicines Corporation, Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics, Deciphera Pharmaceuticals, Philogen, GlaxoSmithKline, Epizyme, Eli Lilly and Company, Pfizer, Aadi Bioscience, Sierra Oncology, Nanobiotix, Taiho Oncology, Arog Pharmaceuticals, Merck Sharp & Dohme and several others are novel developing Soft tissue sarcoma therapies and are advancing the research in STS market for the better treatment approach to STS patients. 

Some of the Soft tissue sarcoma pipeline therapies categorized into the line of therapies they are under development are as follows: 

However, many drugs are going to be launched as more than one-line therapies for different types of sarcomas such as Ripretinib, Avapritinib, Anlotinib, and others. 

The emerging Soft tissue sarcoma therapies are expected to reform the Soft tissue sarcoma market landscape in the coming decade, estimates DelveInsight. Increasing STS incidence, upcoming novel treatment approaches, piqued interest of pharma and biotech players in the field, and contribution from government organizations to advance R&D in the STS will increase the Soft tissue sarcoma market size during the study period 2017-30.